title: Effect of tepoxalin on renal function in healthy dogs receiving an angiotensin-converting enzyme inhibitor.
abstract: The objective of this study was to investigate renal function in clinically normal dogs receiving tepoxalin, a nonsteroidal inflammatory drug, either in association with or without an angiotensin-converting enzyme inhibitor (ACEI). Ten adult female Beagle dogs were used in the three phases of the study. The dogs were administered the drugs once daily for 7 days (experiment 1: placebo/tepoxalin/tepoxalin and benazepril; experiment 2: enalapril/tepoxalin and enalapril) or for 28 days (experiment 3: tepoxalin and benazepril together). Renal function was assessed by measurement of glomerular filtration rate (GFR) by renal scintigraphy [(renal uptake of 99mTc-diethylenetriaminepentacetic acid (DTPA)] and plasma clearance of 99mTc-DTPA. Compared with the placebo group, renal uptake and plasma clearance of 99mTc-DTPA were not significantly modified after a 7-day period of treatment with tepoxalin or enalapril alone, tepoxalin and benazepril or tepoxalin and enalapril together. No significant change was obtained in GFR after a 28-day period of dosing with tepoxalin and benazepril together. Therefore, it was concluded that tepoxalin did not alter renal function in healthy Beagle dogs receiving ACEI.
authors.affiliation: Unité de Physiopathologie Animale et Pharmacologie Fonctionnelle, UPSP, ENV Nantes, Nantes Cedex, France.
authors.forename: M
authors.initials: M
authors.lastname: Fusellier
authors.forename: J-C
authors.initials: JC
authors.lastname: Desfontis
authors.forename: S
authors.initials: S
authors.lastname: Madec
authors.forename: F
authors.initials: F
authors.lastname: Gautier
authors.forename: L
authors.initials: L
authors.lastname: Marescaux
authors.forename: M
authors.initials: M
authors.lastname: Debailleul
authors.forename: M
authors.initials: M
authors.lastname: Gogny
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000097:blood / Q000494:pharmacology*; D001552:Benzazepines / Q000008:administration & dosage / Q000494:pharmacology; D004285:Dogs; D004359:Drug Therapy, Combination; D004656:Enalapril / Q000008:administration & dosage / Q000494:pharmacology; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D007668:Kidney / Q000000981:diagnostic imaging / Q000187:drug effects*; D007677:Kidney Function Tests / Q000662:veterinary; D011720:Pyrazoles / Q000097:blood / Q000494:pharmacology*; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D016284:Technetium Tc 99m Pentetate
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000894:Anti-Inflammatory Agents, Non-Steroidal; D001552:Benzazepines; D011720:Pyrazoles; D019275:Radiopharmaceuticals; D004656:Enalapril; C073135:tepoxalin; C044946:benazepril; D016284:Technetium Tc 99m Pentetate